TR200101868T2 - Sülfonamit hidroksamatlar. - Google Patents

Sülfonamit hidroksamatlar.

Info

Publication number
TR200101868T2
TR200101868T2 TR2001/01868T TR200101868T TR200101868T2 TR 200101868 T2 TR200101868 T2 TR 200101868T2 TR 2001/01868 T TR2001/01868 T TR 2001/01868T TR 200101868 T TR200101868 T TR 200101868T TR 200101868 T2 TR200101868 T2 TR 200101868T2
Authority
TR
Turkey
Prior art keywords
hydroxamates
sulfonamide
sulfonamide hydroxamates
protteinase
char1
Prior art date
Application number
TR2001/01868T
Other languages
English (en)
Inventor
Roland Billedeau Joseph
Chris Broka Allen
Jeffrey Campbell Allen
Jian Chen Jeffrey
Sharon Dankwardt Marie
Delaet Nancy
Leslie Robinson Ann
Adrian Keith Walker Murray
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR200101868T2 publication Critical patent/TR200101868T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Bu bulus, prokolajen C-protteinaz önleyicileri olan formül (Ia)'ya ait usülfonamit türevleriyle (buradaki R, -CH(R2)Ar1 veya-CH(R2)CH=CHAr1,dir ve diger degiskenler, istemlerde tanimlandigi gibidir), bunlari ihtiva eden farmakolojik kompozisyonlarla, bunlarin kullanimlariyla ve bu bilesiklerin hazirlanmasina yönelik metotlarla ilgilidir.
TR2001/01868T 1998-12-22 1999-12-14 Sülfonamit hidroksamatlar. TR200101868T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11331198P 1998-12-22 1998-12-22
US14705399P 1999-08-03 1999-08-03

Publications (1)

Publication Number Publication Date
TR200101868T2 true TR200101868T2 (tr) 2001-11-21

Family

ID=26810914

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01868T TR200101868T2 (tr) 1998-12-22 1999-12-14 Sülfonamit hidroksamatlar.

Country Status (22)

Country Link
EP (1) EP1149072B1 (tr)
JP (1) JP2002533322A (tr)
KR (1) KR20010101312A (tr)
CN (1) CN1331674A (tr)
AT (1) ATE270271T1 (tr)
AU (1) AU769319B2 (tr)
BR (1) BR9916504A (tr)
CA (1) CA2355902A1 (tr)
CZ (1) CZ20012294A3 (tr)
DE (1) DE69918465D1 (tr)
HK (1) HK1042691A1 (tr)
HR (1) HRP20010443A2 (tr)
HU (1) HUP0104658A3 (tr)
IL (1) IL143625A0 (tr)
MA (1) MA26767A1 (tr)
NO (1) NO20013100L (tr)
NZ (1) NZ512292A (tr)
PL (1) PL349449A1 (tr)
RU (1) RU2232751C2 (tr)
TR (1) TR200101868T2 (tr)
WO (1) WO2000037436A1 (tr)
YU (1) YU44901A (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
GB0108097D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
JP2005500287A (ja) * 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
MXPA05008106A (es) * 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
WO2005023257A1 (en) * 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
NZ549962A (en) * 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
WO2010007027A1 (en) * 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8354548B2 (en) * 2010-02-19 2013-01-15 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
JPWO2012165262A1 (ja) * 2011-05-27 2015-02-23 国立大学法人徳島大学 ベンジルアミン誘導体
AU2015205370B2 (en) 2014-01-10 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
KR19990036271A (ko) * 1995-08-08 1999-05-25 토마스 네프 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 ｃ-프로테나제 저해물질

Also Published As

Publication number Publication date
RU2232751C2 (ru) 2004-07-20
NO20013100D0 (no) 2001-06-21
ATE270271T1 (de) 2004-07-15
CA2355902A1 (en) 2000-06-29
IL143625A0 (en) 2002-04-21
KR20010101312A (ko) 2001-11-14
AU769319B2 (en) 2004-01-22
NZ512292A (en) 2004-03-26
WO2000037436A1 (en) 2000-06-29
HK1042691A1 (zh) 2002-08-23
PL349449A1 (en) 2002-07-29
NO20013100L (no) 2001-08-21
MA26767A1 (fr) 2004-12-20
HUP0104658A3 (en) 2005-12-28
EP1149072B1 (en) 2004-06-30
CN1331674A (zh) 2002-01-16
CZ20012294A3 (cs) 2001-12-12
AU1979200A (en) 2000-07-12
DE69918465D1 (de) 2004-08-05
BR9916504A (pt) 2001-09-11
YU44901A (sh) 2003-12-31
HUP0104658A2 (en) 2002-06-29
EP1149072A1 (en) 2001-10-31
HRP20010443A2 (en) 2002-06-30
JP2002533322A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
TR200101868T2 (tr) Sülfonamit hidroksamatlar.
ATE306261T1 (de) Antithrombosemittel
DE69830504D1 (de) Antithrombotische mitteln
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
ATE273305T1 (de) Thrombin-inhibitoren
NO20003018D0 (no) Triazinangiogenese-inhibitorer
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
YU40997A (sh) Novi oksadiazoli, postupci za njihovo pripremanje
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
EA200500814A1 (ru) Производные пирролопиримидина
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
EA200100983A1 (ru) Производные 13-метилэритромицина
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
NO975028L (no) Piperazinoderivater som neurokininantagonister
ATE308540T1 (de) Antithrombosemittel
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen